| Project/Area Number |
23KJ1296
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 国内 |
|---|
| Review Section |
Basic Section 49070:Immunology-related
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
RONG XINGYU 京都大学, 医学研究科, 特別研究員(DC2)
|
|---|
| Project Period (FY) |
2023-04-25 – 2025-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 2024: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2023: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Outline of Research at the Start |
In this study we carried out a well-designed CRISPR screening in which we transduced the cells with PD-L1-3’UTR. In this case, we can find out the RNA-binding proteins which can directly decay PD-L1 mRNA, which so far remains elusive. We will investigate the underlying mechanism of how the candidate RBP delays PD-L1 mRNA, and provide new insights into regulation of RBPs in anti-tumor immunity. So far, clinical research has proven that only few strategies may be efficient in reducing PD-L1.We will provide a novel therapeutic strategyto promote the efficacy of immunotherapy to tumor patients.
|
